If you have been reading about Thymalfasin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Regenerating islet-derived protein 3 gamma (also Regenerating islet-derived protein III-gamma) is a protein that in humans is encoded by the REG3G gene. Intestinal paneth cells produce REG3G (or REG3 gamma) via stimulation of toll-like receptors (TLRs) by pathogen-associated molecular patterns (PAMPs). REG3 gamma specifically targets Gram-positive bacteria because it binds to their surface peptidoglycan layer. It is one of several antimicrobial peptides produced by paneth cells.
=== Heritage Conservation Areas === Holyhead has three officially designated Conservation Areas. Holyhead Central Conservation Area covers the historic Old Town core that developed around the Roman Fort. Holyhead Beach Conservation Area in located in the Newry promenade area, and Holyhead Mountain Conservation Area is located north of the village of Llaingoch.
== Adverse effects == Besides being a hepatocarcinogen, safrole exhibits further adverse effects in that it will induce the formation of hepatic lipid hydroperoxides. Safrole also inhibits the defensive function of neutrophils against bacteria. In addition to the inhibition of the defensive function of neutrophils, it has also been discovered that safrole interferes with the formation of superoxides by neutrophils. Furthermore, safrole oxide, a metabolite of safrole, has a negative effect on the central nervous system. Safrole oxide inhibits the expression of integrin β4/SOD, leading to apoptosis of the nerve cells.
On August 31, 2022, FIFA president Gianni Infantino confirmed that six CONCACAF teams would qualify for the World Cup, with Canada, Mexico, and the United States automatically qualifying as hosts. This was confirmed by the FIFA Council on February 14, 2023. Immediately prior to the 67th FIFA Congress, the FIFA Council approved the slot allocation during a meeting in Manama, Bahrain. This included an inter-confederation playoff tournament involving six teams to decide the last two FIFA World Cup spots. The six teams in the playoffs comprised one team from each confederation excluding UEFA, and one additional team from the confederation of the host countries (CONCACAF). Two of those teams were seeded based on the World Rankings, and they played the winners of two knockout matches between the four unseeded teams for the two FIFA World Cup berths. The four-match tournament was played in Mexico, one of the host countries, and was also used as a test event for the FIFA World Cup. The ratification of slot allocation also gave the OFC a guaranteed berth in the final tournament for the first time: the 2026 FIFA World Cup was the first tournament in which all six confederations had at least one guaranteed berth and also the first time since the 2010 edition in which all confederations had a team qualify for the World Cup finals. Of the 48 qualified teams, 26 also appeared in the 2022 edition. Highlights include:
Despite his future success, Fenn always felt that his lack of mathematical skills were a hindrance in his career. After submitting several applications, Fenn received offers for teaching assistantships from Yale and Northwestern, and accepted the position at Yale. Fenn did his graduate studies in physical chemistry under Gosta Akerlof. He obtained his PhD in chemistry from Yale in 1940 and his thesis was 45 pages long, with only three pages of prose.
Sources: en.wikipedia.org
==== The Annona ==== The first indication of a collective, organized food distribution system within the Roman Republic comes from the annona. Originally meaning "yearly return", the annona became the administrative term for governmental bread and grain distribution. Over time, annona came to represent the distribution of all pertinent foods in the Roman diet. The annona was originally organized between 500 and 50 BCE, and gained increasing influence in the centuries to come. The practice of specifically distributing grain to the plebeian class, known as frumentationes, gained prominence around 120 BCE and supplemented the efforts of the annona to feed the Roman people. Emperor Augustus officially changed the annona system between 8 and 14 CE. He established the position of praefectus annonae, Prefect of the Annona. Up to this point in time, the annona was handled by local government officials called aediles. Augustus’ Prefect of the Annona oversaw all transportation, weighing, inspection, and storing of state foods. The physical distribution of foods throughout the Roman Empire varied by location and type of food. Some foods were shipped by boat and then distributed once they reached port. Others, specifically meat, were transported by land and brought into urban areas. Special regulations were put in place for the distribution of olive oil, as the Empire made contracts with olive oil producers all over the Mediterranean. Free daily distributions of olive oil were enacted by Emperor Severus during his reign from 192 to 211 CE.
The great danger of our situation consists in the fact that on the one hand, this is a war whose direction and decision are in the hands of the great powers engaged in it for life or death, and at the same time, we do not have a repertoire of tangible objectives to mark and govern our path... no pending territorial dispute... an invasion... we do not even have a common border with enemy countries.... We run the risk of entering into a rather ideological war of solidarity with the United States of America.... Under these conditions we are seriously exposed to a deadly annulment of our national personality. Nonetheless, labour leader and head of the Mexican left Vicente Lombardo Toledano supported the allied cause in the tribunes and advised the president not to take refuge in prudence because the time had come for the country to honor its traditions. The idea of national unity prevailed, and 1942 was declared the "Year of Effort", with the multiplication in all the media of allusive messages always accompanied by a Mexican flag such as:
== Drug pricing issue and exit in the Swiss market == In July 2025, Roche withdrew Lunsumio from the Swiss market following failed price negotiations with the Swiss Federal Office of Public Health (BAG). The drug had been available since February 2023 through a special "Early Access" program that allowed reimbursement before complete clinical data was available. Under this arrangement, Roche initially covered treatment costs until efficacy was demonstrated, after which the remaining therapy could exceed 100,000 Swiss francs. When Swissmedic extended the temporary authorization in February 2025 due to still-missing complete clinical data from Phase III studies, Roche rejected the previously negotiated pricing model and demanded higher prices. The BAG refused to modify the agreement, citing concerns that exceptions would set a precedent for other pharmaceutical companies and demanding additional efficacy evidence despite the drug showing positive effects in Phase II studies. According to Swissmedic pricing data, a single 60-mg dose (two vials) of Lunsumio costs over 7,000 Swiss francs. The withdrawal was announced to oncologists on July 1, 2025, affecting approximately 24 patients annually who suffer from follicular lymphoma—a slowly progressing cancer of the lymph nodes with about 500 new cases per year in Switzerland. Roche also refused to provide individual case reimbursements—a standard Swiss mechanism for exceptional medical situations.
Protein primary structure is the linear sequence of amino acids in a peptide or protein. By convention, the primary structure of a protein is reported starting from the amino-terminal (N) end to the carboxyl-terminal (C) end. Protein biosynthesis is most commonly performed by ribosomes in cells. Peptides can also be synthesized in the laboratory. Protein primary structures can be directly sequenced, or inferred from DNA sequences.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.